Carrying out in vivo studies in a relevant background and within the context of drug resistance and advanced metastatic disease will be of particular importance in further defining the role of PRK2 as a potential therapeutic target and thus help inform the development of novel small-molecule PRK inhibitors. This evidence concerns the gene PKN2 and metastatic neoplasm.